{
  "story_id": "3366e849b6edf79b4564d8e2dd393946",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-11-20T14:20:25.000Z",
  "content_hash": "386d72fc79f74a2edc4f29d264ad49bc147d0d693c54f8507466294864c628b2",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Study finds malaria monoclonal antibody interferes with R21 vaccine response",
    "dek": "New research shows L9LS malaria antibody reduces R21 vaccine immune response in infants.",
    "prose": "Researchers presented on Thursday at the American Society of Tropical Medicine and Hygiene annual meeting that L9LS monoclonal antibody was 78% effective against malaria over six months in Malian infants versus placebo. [^1]\n\nStudy researchers reported that administering L9LS prior to R21 malaria vaccine reduced vaccine-induced antibody levels by 20% to 30% in tested infants. [^2] The PfSPZ-LARC2 malaria vaccine achieved 87% efficacy in preventing infection during a Phase 1 trial. [^3] Researchers identified pregnant people and children recently discharged after malaria hospitalization as priority groups for future L9LS testing. [^4]\n\nStudy lead Robert Seder stated that researchers will prioritize non-infant patient groups for L9LS pivotal trials planned to start in 2028. [^5] In the trial, all 7 placebo recipients became infected after malaria challenge, while only 2 of 15 vaccinated participants developed infection. [^6] The PfSPZ-LARC2 vaccine was found to be safe and well tolerated by trial participants. [^7]\n\nDr. Sean C. Murphy led reporting of the trial findings, with trial operations led by UW Medicine and partner institutions. [^8]",
    "cited": "[{\"statement\":\"Researchers presented on Thursday at the American Society of Tropical Medicine and Hygiene annual meeting that L9LS monoclonal antibody was 78% effective against malaria over six months in Malian infants versus placebo.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-19T22:20:00.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"],\"url\":\"https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss\"},{\"statement\":\"Study researchers reported that administering L9LS prior to R21 malaria vaccine reduced vaccine-induced antibody levels by 20% to 30% in tested infants.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-19T22:20:00.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"],\"url\":\"https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss\"},{\"statement\":\"The PfSPZ-LARC2 malaria vaccine achieved 87% efficacy in preventing infection during a Phase 1 trial.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T14:20:25.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-malaria-vaccine-efficacy-clinical-trial.html\"},{\"statement\":\"Researchers identified pregnant people and children recently discharged after malaria hospitalization as priority groups for future L9LS testing.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-19T22:20:00.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"],\"url\":\"https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss\"},{\"statement\":\"Study lead Robert Seder stated that researchers will prioritize non-infant patient groups for L9LS pivotal trials planned to start in 2028.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-19T22:20:00.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"],\"url\":\"https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss\"},{\"statement\":\"In the trial, all 7 placebo recipients became infected after malaria challenge, while only 2 of 15 vaccinated participants developed infection.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T14:20:25.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-malaria-vaccine-efficacy-clinical-trial.html\"},{\"statement\":\"The PfSPZ-LARC2 vaccine was found to be safe and well tolerated by trial participants.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T14:20:25.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-malaria-vaccine-efficacy-clinical-trial.html\"},{\"statement\":\"Dr. Sean C. Murphy led reporting of the trial findings, with trial operations led by UW Medicine and partner institutions.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T14:20:25.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-malaria-vaccine-efficacy-clinical-trial.html\"}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": {
    "slice_hash": "c62b69a244965f99bcf421ff384e9f724809f1824ad0ed588438d26c6b2d9d8d",
    "cursor_from": "ingest:raw_newsroomfloor.stories:c62b69a244965f99",
    "cursor_to": "ingest:raw_newsroomfloor.stories:c62b69a244965f99",
    "view": "ingest:raw_newsroomfloor.stories",
    "view_version": "1",
    "row_count": 1,
    "hash_basis": "sha256 over the JSON array of {insertId, json} rows as received (normalized wire shape), computed before the BigQuery forward",
    "credits": 0.01,
    "price_per_100_rows_written": 1,
    "sig": "G8nfxzAFRp9Rm3AjDyDjjQSJxzdkJe9eBBaoaNfU_5dRP-dFEb53ifeBWuwfcsbB3i8f-9Q2YW0mIBeYwdCCDA",
    "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
    "signer_path": "lakehouse/data-extract/v1",
    "alg": "Ed25519",
    "signed": true
  },
  "receipt_note": "the ingest door's signed receipt for this revision, verbatim as the door returned it",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "3a8a1f8c8e70ee6bfba3a00e986bc818",
      "thread_id": "cb16bd995202e48bc981fcbcdf0e9382",
      "thread_label": "American Society of Tropical Medicine and Hygiene",
      "novelty": "UPDATE",
      "content_hash": "f1718a0bfe784cc6063c543b18346ca36228d06bc4adcafa6aee15f95538289a",
      "compose": 3,
      "last_published_at": "2026-11-20T14:20:25.000Z",
      "read_receipt": {
        "slice_hash": "6dc2d9e58f101533d1e559a5955738d51186a526bc58d869d246f3a3b034ec0e",
        "cursor_from": "eyJ0cyI6IjIwMjYtMTEtMjBUMTI6MDQ6MDcuMDAwMDAwWiIsImlkIjoiN2RlMGFkNzY0ODgwMzFmOWU4ZjI4MjA3MDRmNzU2MWYiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMTEtMjBUMTc6Mzc6MTAuMDAwMDAwWiIsImlkIjoiOWVlYmVlZjgyMWM1MTExMmU1NzI0MDA2ZWNkYzhjZjEiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 85,
        "window_days": 3,
        "bytes_scanned": 0,
        "credits": 6.8,
        "price_per_100_rows": 8,
        "sig": "_hJHnighuv48Tg7XmmVqJF_QY2gY-AFadxPDapix90LcYk6X9YJMGLVZmqesd6RV_gEAnM7mie4fCM0smLPzCg",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "landing": "air"
    },
    "written_at": "2026-11-20T18:31:01.709Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "Researchers presented on Thursday at the American Society of Tropical Medicine and Hygiene annual meeting that L9LS monoclonal antibody was 78% effective against malaria over six months in Malian infants versus placebo.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "Study researchers reported that administering L9LS prior to R21 malaria vaccine reduced vaccine-induced antibody levels by 20% to 30% in tested infants.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "The PfSPZ-LARC2 malaria vaccine achieved 87% efficacy in preventing infection during a Phase 1 trial.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-malaria-vaccine-efficacy-clinical-trial.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "Researchers identified pregnant people and children recently discharged after malaria hospitalization as priority groups for future L9LS testing.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "Study lead Robert Seder stated that researchers will prioritize non-infant patient groups for L9LS pivotal trials planned to start in 2028.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 6,
      "statement": "In the trial, all 7 placebo recipients became infected after malaria challenge, while only 2 of 15 vaccinated participants developed infection.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-malaria-vaccine-efficacy-clinical-trial.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 7,
      "statement": "The PfSPZ-LARC2 vaccine was found to be safe and well tolerated by trial participants.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-malaria-vaccine-efficacy-clinical-trial.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 8,
      "statement": "Dr. Sean C. Murphy led reporting of the trial findings, with trial operations led by UW Medicine and partner institutions.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-malaria-vaccine-efficacy-clinical-trial.html",
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}